Clinical trials: Dementia Disorders
Alzheimer's Disease
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
- Trial name
- CONCERT (NCT00829374)
- Testing
- Dimebon
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 1,003 people
- Sponsor
- Medivation, Inc.
Mild to Moderate Alzheimer's Disease
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.
- Trial name
- NCT03625622
- Testing
- AR1001
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- AriBio Co., Ltd.
Alzheimer's Disease
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.
- Trial name
- NCT00478205
- Testing
- Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
- Where
- United States
- Volunteers
- 1,467 people
- Sponsor
- Eisai Inc.
Alzheimer Disease, Dementia
IONA Longitudinal Cohort Study
Understanding more about how diseases that cause dementia develop is critical as the number of people living with, or affected by, dementia in Scotland continues to grow.
- Trial name
- IONA LCS (NCT05892952)
- Where
- United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Brain Health Scotland Life Sciences Ltd
Alzheimer's Disease
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
Multi-centre study of HTL0018318 in patients with Alzheimer's disease as an add-on to standard-of-care
- Trial name
- NCT03456349
- Testing
- HTL0018318
- Where
- 4 sites in Czechia, Poland and 2 more
- Volunteers
- 60 people
- Sponsor
- Nxera Pharma UK Limited
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping
The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Trial name
- EARS (NCT04928690)
- Volunteers
- 140 people
- Sponsor
- Novoic Limited
Alzheimer's Disease
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate.
- Trial name
- NCT00090116
- Testing
- Neramexane
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Forest Laboratories
Alzheimer Disease
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with…
- Trial name
- NCT05531526
- Testing
- AR1001
- Where
- 198 sites in United States, Canada and 11 more
- Volunteers
- 1,535 people
- Sponsor
- AriBio Co., Ltd.
Alzheimer's Disease
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants
This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous…
- Trial name
- NCT07889349
- Testing
- SHR 3201 Injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Dementia With Lewy Bodies (DLB)
A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).
- Trial name
- NCT00543855
- Testing
- 3 mg Donepezil hydrochloride, 5 mg Donepezil hydrochloride, 10 mg Donepezil hydrochloride
- Where
- 43 sites in Japan
- Volunteers
- 167 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- EMERGE (NCT02484547)
- Testing
- Aducanumab (BIIB037)
- Where
- 180 sites in United States, Belgium and 11 more
- Volunteers
- 1,643 people
- Sponsor
- Biogen
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
This Phase I clinical study is a randomized, double-blind, placebo-controlled, parallel-design study to thoroughly assess the safety profile and PK properties of J147 in healthy subjects.
- Trial name
- NCT03838185
- Testing
- J147
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
- Trial name
- NCT00160147
- Testing
- bifeprunox
- Where
- 51 sites in United States, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Solvay Pharmaceuticals
TTR-mediated Amyloidosis
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
- Trial name
- NCT02292186
- Testing
- Revusiran (ALN-TTRSC)
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 25 people
- Sponsor
- Alnylam Pharmaceuticals
Agitation,Psychomotor, Dementia
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years…
- Trial name
- TRANQUILITY (NCT04251910)
- Testing
- Sublingual film containing Dexmedetomidine
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- BioXcel Therapeutics Inc
Alzheimer's Disease
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24).
- Trial name
- NCT00428389
- Testing
- Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
- Where
- 23 sites in United States
- Volunteers
- 262 people
- Sponsor
- Novartis
Alzheimer's Disease
Observational Study Of Donepezil In Routine Clinical Practice
To characterize the comorbidities and medications of patients treated with donepezil in a routine clinical practice and to verify the therapeutic response of these patients.
- Trial name
- NCT00843115
- Testing
- donepezil
- Volunteers
- 370 people
- Sponsor
- Pfizer
Alzheimer's Disease
Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease
The purpose of this observational study is to determine whether the vaccine (UB 311), targeting the N-terminal amino acids (1-14) of the amyloid beta peptide, has long-term immunogenicity and efficacy in individuals diagnosed…
- Trial name
- NCT01189084
- Testing
- Observational
- Where
- 2 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- United Biomedical
Dementia
Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)
The drug, scopolamine, can result in short-term impairments of cognitive function, attention, and memory that resemble those seen in aging and Alzheimer's disease.
- Trial name
- NCT01181310
- Testing
- C: MK-3134 25 mg + Scopolamine 0.5 mg, D: Donepezil 10 mg + Scopolamine 0.5 mg, E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.